A clinical study conducted in China comparing the composition of the gut microbiome of patients with POAG with a control group found that patients with POAG had an increase in the relative abundance of the bacterial family
Prevotellaceae and unidentified
Enterobacteriaceae.
13 In contrast, the bacterial genus
Megamonas was more prevalent in the control group. Another study in Europe found an increased abundance of
Escherichia coli species in patients with POAG and more
Bacteroides plebeius in the control group.
14 Both
Prevotella spp. and
E.coli have proinflammatory properties. In AMD, two clinical studies conducted in Switzerland on patients with neovascular AMD found that the
Firmicutes phylum was more prevalent in AMD patients compared with the control group.
18,19 The relative abundance of
Anaerotruncus and
Oscillibacter was increased in AMD patients compared with controls.
18 For DR, studies have been conducted in India and China. In the Indian study, the abundance of the
Actinobacteria phylum was lower in patients with DR.
15 In contrast, in the Chinese study, there was a decrease in the abundance of the
Firmicutes phylum in patients with DR.
16 However, in another study conducted in India comparing diabetics with and without DR, no difference was found between the two groups.
17 Nevertheless, the study suggested that the relative abundance ratio of Bacteroides to Firmicutes (B/F ratio) could be considered as a DR developmental marker.
17 Altogether, these data suggest that the gut microbiome differs across diseases, although factors such as sample size, age, host genetics, and environmental factors, as well as independent cohorts, could contribute.